Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Chronic lymphocytic leukemia
Phase 2 LP-168 small molecule inhibitor and obinutuzumab CD20 mAb in CLL/SLL.
This multicenter parallel 2-cohort trial evaluates LP-168 with obinutuzumab in previously treated CLL/SLL patients, including those with a BTK gatekeeper T474 mutation. The study aims to assess safety and preliminary…
NCT06978088 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 3 Study: Sonrotoclax, BCL2 Inhibitor, with Anti-CD20 Therapies in R/R CLL/SLL.
This trial compares sonrotoclax combined with anti-CD20 antibodies to standard venetoclax plus rituximab in adults with relapsed/refractory CLL/SLL receiving second-line or later therapy. Conducted at multiple…
NCT06943872 Registrational - New trial
Acute myeloid leukemia and MDS
Phase 1 Trial of miRisten, a cell growth molecule blocker, for relapsed/refractory AML
This Phase 1 trial at City of Hope Medical Center evaluates miRisten administered via IV infusion on a multi-day schedule to determine its safety, tolerability, and optimal dosing in adult patients with…
NCT07025564 First-in-human - New trial
Acute myeloid leukemia and MDS
Phase 1 trial of atezolizumab PD-L1 mAb combined with CIML natural killer cells in AML.
This study aims to determine the maximum tolerated dose of cytokine-induced memory-like NK cells with atezolizumab and IL-2 in relapsed/refractory acute myelogenous leukemia. Participants have various genetic AML…
NCT07011004 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1b dexamethasone (glucocorticoid) plus venetoclax trial in treatment-naïve AML.
This investigator-initiated single-arm study at the University of Vermont evaluates the safety and tolerability of adding dexamethasone to venetoclax-based low-intensity therapy in adult AML patients ineligible for…
NCT07014462 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1 study of ERAS-0015, a RAS inhibitor small molecule.
This open-label study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of ERAS-0015 administered alone or with additional investigational agents in patients with advanced or metastatic…
NCT06983743 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 TNG462 PRMT5 inhibitor trial with KRAS inhibitor combinations.
This open-label, multicenter trial evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral TNG462 combined with investigational KRAS agents RMC-6236 or RMC-9805…
NCT06922591 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 trial ARV-806 KRAS (G12D) inhibitor in advanced cancer.
This open-label Phase 1/2 study evaluates ARV-806 administered via IV infusion in adults with advanced KRAS G12D-mutated tumors, including metastatic pancreatic ductal adenocarcinoma. Sponsored by Arvinas Inc. and…
NCT07023731 First-in-human - New trial
Multiple solid tumors
Phase 1/2 Patritumab Deruxtecan, HER3-directed Topoisomerase I Inhibitor ADC
The study evaluates safety, PK, and efficacy of patritumab deruxtecan as monotherapy in children with relapsed or refractory hepatoblastoma or rhabdomyosarcoma, given via IV every 3 weeks. The trial, conducted by…
NCT06941272 Exploratory - New trial
Multiple solid tumors
Phase I/II trial: DT2216, a BCL‑xL degrader, combined with irinotecan for refractory pediatric cancers
This phase I/II trial by the Children’s Oncology Group evaluates the safety, tolerability, and preliminary efficacy of DT2216 with irinotecan in children, adolescents, and young adults with relapsed or refractory…
NCT06620302 Exploratory - New trial
Multiple solid tumors
Phase 1b/2 Evorpacept trial: CD47-binding Ig Fc fusion protein in oncology.
This study evaluates evorpacept in combination with anti-cancer therapies in advanced and metastatic tumors. The trial enrolls patients with HER2+ breast, colorectal, and head and neck cancers in both randomized and…
NCT07007559 Exploratory - New trial
Multiple solid tumors
Phase 1 AB821 trial of CD8-targeted IL-21 immunotherapy.
This open-label, dose-escalation study at Yale University in New Haven evaluates AB821 monotherapy given every 2 weeks in adults with recurrent, locally advanced or metastatic melanoma and other immune-responsive…
NCT07027488 First-in-human - New trial
Multiple solid tumors
Phase 1b [225Ac]Ac-AKY-1189 Nectin-4 Radiopharmaceutical, a Nectin-4-directed alpha emitter.
This first-in-human, two-part study led by Aktis Oncology evaluates the safety and maximum tolerated dose of [225Ac]Ac-AKY-1189 monotherapy in patients with advanced or metastatic solid tumors. Conducted at Grand…
NCT07020117 First-in-human - New trial
Multiple solid tumors
Phase 1 Study of BL-M17D1: HER2-directed mAb Auristatin (tubulin inhibitor) ADC
This Phase 1 open-label trial, sponsored by SystImmune Inc., assesses BL-M17D1 administered every three weeks in patients with HER2-expressing or HER2-mutated advanced/metastatic solid tumors. The study includes…
NCT06714617 First-in-human - New trial
Multiple solid tumors
Phase 1/2 trial of CGT4859, an FGFR2/3 inhibitor, in advanced solid tumors
This open-label study evaluates the safety, dosing, and antitumor activity of oral CGT4859 administered via dose escalation and expansion in adults with unresectable or metastatic intrahepatic cholangiocarcinoma and…
NCT06777316 First-in-human - New trial
Multiple solid tumors
Phase III RT Trial: VLDRT as ionizing radiation for DNA damage in indolent lymphomas
Memorial Sloan Kettering Cancer Center is investigating whether very low dose radiotherapy (4 Gy in 1-2 fractions) is as effective as standard treatment (24 Gy in 12 fractions) for untreated indolent B-cell lymphomas…
NCT07029217 Registrational - New trial
Multiple solid tumors
Phase 1/2 trial of AVZO-023, a CDK4/CDK6 inhibitor.
This trial by Avenzo Therapeutics assesses AVZO-023 safety and antitumor activity as monotherapy and in combination with AVZO-021, fulvestrant, or letrozole in patients with advanced solid tumors including HR+/HER2-…
NCT06998407 First-in-human - New trial
Multiple solid tumors
Phase 1 VIR-5525 EGFR-directed T-cell engager trial.
This first-in-human study evaluates VIR-5525 as monotherapy and with pembrolizumab in dose-escalation and expansion cohorts for locally advanced or metastatic solid tumors expressing EGFR, including HNSCC, CRC, and…
NCT06960395 First-in-human - New trial
Multiple solid tumors
Phase 1 study of NKT5097, a CDK2/CDK4/6 inhibitor for advanced solid tumors.
This open-label study evaluates the safety, tolerability, and pharmacokinetics of NKT5097 in adults with advanced/metastatic solid tumors, including breast cancer and CCNE1-amplified cases. The trial features dose…
NCT07029399 First-in-human - New trial
Multiple solid tumors
Phase 1 trial of [Ga-68]MTP220, targeted PET tracer.
This first-in-human, single-arm open-label study evaluates the safety and imaging efficacy of a one-time injection of [Ga-68]MTP220 followed by serial PET/CT scans during a 2.5-hour session. It enrolls newly…
NCT07026981 First-in-human - New trial
Multiple solid tumors
Phase 1 Tirbanibulin Ointment DNA synthesis inhibitor trial for keratinocyte carcinomas
This trial evaluates fractional laser therapy alone versus in combination with tirbanibulin ointment for treating squamous and basal cell carcinomas. Eligible first-line patients with superficial to invasive…
NCT07010692 Exploratory - New trial
Multiple solid tumors
Phase 1/2a VS-7375 trial: KRAS G12D inhibitor for advanced solid tumors
This open-label study evaluates VS-7375 alone or with cetuximab in patients with advanced metastatic solid tumors harboring KRAS G12D mutations, including pancreatic, lung, and colorectal cancers. The trial aims to…
NCT07020221 First-in-human - New trial
Multiple solid tumors
Phase 1 PF-08046031 anti-CD228 ADC trial for advanced melanoma and solid tumors.
This open-label Phase 1 study evaluates PF-08046031 as monotherapy in adults with metastatic melanoma and other advanced solid tumors lacking approved treatment options. The trial, conducted by Pfizer at sites…
NCT06799533 First-in-human - New trial
Multiple solid tumors
Phase 1 ARC101 CLDN6-directed T-cell receptor engager trial in advanced cancers.
A first-in-human trial assessing escalating doses and expansion cohorts of ARC101 as monotherapy in patients with advanced or metastatic solid tumors, including testicular and ovarian cancers expressing CLDN6. This…
NCT06672185 First-in-human - New trial
Multiple solid tumors
Phase 1/2 ETX-636 pan-mutant-selective PI3Kα inhibitor trial
This open-label study evaluates ETX-636 as monotherapy in advanced solid tumors with PIK3CA mutations and in combination with fulvestrant in HR+/HER2- metastatic breast cancer. Conducted by Ensem Therapeutics in…
NCT06993844 First-in-human - New trial Spotlight
Other blood cancers and transplant
Phase 1 trial of ruxolitinib, a JAK1 inhibitor for preventing GVHD
Investigating biomarker-guided ruxolitinib for preventing chronic GVHD in post-transplant patients, this Phase 1 trial compares ruxolitinib monotherapy starting about 105 days after allogeneic HCT versus…
NCT07025538 Exploratory - New trial
Other blood cancers and transplant
Phase 1 HaploCord Transplant: Unmodified cord blood graft for hematologic malignancies.
This trial at Case Comprehensive Cancer Center in Cleveland investigates whether combining haplo‐identical donor and cord blood transplants can yield durable disease‐free survival in patients with AML or ALL.…
NCT06904482 Exploratory - New trial
Other blood cancers and transplant
Phase 1 study: Tetrahydrouridine-Decitabine, DNA methyltransferase and cytidine deaminase inhibitor combo.
This Phase 1 trial from EpiDestiny, Inc. evaluates weekly oral administrations of tetrahydrouridine followed by decitabine over 24 weeks in patients with relapsed or refractory myelodysplastic syndromes. The study…
NCT07006025 Exploratory - Trial result Spotlight
Breast cancer
T-DXd Outscores T-DM1 Across HER2 Copy-Number, PI3K, and HRD Genomic Subsets in DESTINY-Breast03
In this ctDNA biomarker dive from the Phase III DESTINY-Breast03 trial (n≈420), researchers profiled >700 genes at baseline and progression. Despite wide heterogeneity—PIK3CA 48%, TP53 73%, HER2 amplifications…
- Trial result Spotlight
Breast cancer
Gedatolisib (pan-PI3K/mTOR) Triplet Hits 85% ORR in HR+/HER2- mBC
Gedatolisib 180 mg IV weekly plus palbociclib and letrozole/fulvestrant was explored in the phase 1b NCT02684032 dose-expansion (four cohorts by prior therapy). ORR reached 85% with 72% 12-mo PFS in treatment-naïve…
NCT02684032
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.